Healthspan vs lifespan

Two different things to want

Lifespan is how long you live. Healthspan is how long you live without significant disease or disability. The gap between them is the part nobody wants, and it is larger than most people expect.

Analyses using WHO data have put the global average gap at roughly a decade — around ten years of life lived in poor health at the end — with the gap wider in wealthier countries and wider in women than men. Costa Rica has a notably high life expectancy for its income level, which is a genuine public health achievement; whether its healthspan gap differs from the regional pattern is not something we have been able to establish from a source we would trust.

Why the gap has been growing

Largely because medicine got better at preventing death from conditions it cannot cure. Treating heart failure, cancer and stroke more effectively converts some rapid deaths into long periods of managed illness.

That is a real victory and an incomplete one. It is also the reason "compression of morbidity" — pushing illness into a shorter window at the end rather than extending the window — became the stated goal of geroscience rather than simply adding years.

What the evidence actually supports

This is where the field divides sharply, and a clinic's honesty is visible in how it handles the division.

Strongly supported, unglamorous, and mostly free:

• Not smoking — still the single largest modifiable factor in both lifespan and healthspan
• Physical activity, with cardiorespiratory fitness among the strongest predictors of mortality in observational data, and muscle strength independently associated with outcomes in older adults
• Blood pressure control
• Sleep, adequate and regular
• Alcohol, where the old "moderate drinking is protective" finding has been substantially undermined by studies correcting for the fact that many abstainers had stopped because they were already unwell
• Social connection, which performs better in the data than most interventions sold at a price

Promising in animals, unproven in humans: caloric restriction and its mimetics, rapamycin, senolytics, NAD precursors, metformin for non‑diabetics. The TAME trial, designed to test whether metformin delays ageing‑related disease in people, has faced years of funding difficulty and has not reported.

The honest summary is that no intervention has been shown in humans to extend healthspan by slowing ageing itself. Anything sold on that basis is sold ahead of the evidence.

Why this clinic measures what it measures

The conditions that consume healthspan in this population — type 2 diabetes, cardiovascular disease, fatty liver, the consequences of untreated hypertension — are the conditions a seven‑marker metabolic panel speaks to.

That is a deliberately modest claim. Measuring glucose, lipids, liver, kidney and thyroid is not slowing ageing. It is finding the specific, common, treatable things that take years off a healthy life, early enough to do something about them.

A clinic promising more than that is promising something nobody can currently deliver.

The part that is not medical

Worth saying, because a clinic has an obvious incentive not to. Much of the variation in healthspan is explained by things no clinic touches: income, education, housing, air quality, occupational exposure, and whether anyone is looking after you when you cannot look after yourself.

Costa Rica's own life expectancy is frequently attributed to factors of this kind — universal healthcare access, social cohesion, diet patterns — rather than to any clinical intervention.

A test worth applying to anyone selling longevity

1. Does the evidence cited come from humans, or from mice and worms?
2. Does it measure a disease outcome, or a biomarker assumed to stand for one?
3. Is the intervention registered for anything, and if used off‑label, is that said plainly?
4. What would the honest answer to "we do not know" look like here — and has anyone given it?

The boundary

Nothing on this page will extend your healthspan. What it may do is set expectations: the gains available with confidence today come from finding and treating ordinary conditions early, and from a short list of unfashionable habits. The exciting part of this field is real research, and it is not yet a service anyone can sell you.